The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.
FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Validation of Improved QoL Assessment for Moderate Psoriasis
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Psoriasis and Sunburn: New Study Highlights Increased Risk and Clinical Implications
Recognizing Barriers to Access Psoriasis Biologics